In Focus Stocks: Amber Road (NYSE:AMBR), Sarepta Therapeutics (NASDAQ:SRPT), Titan Pharmaceuticals (NASDAQ:TTNP), ECA Marcellus Trust I (NYSE:ECT)

Potash Corporation of Saskatchewan Inc. (NYSE:POT) shares moved up 0.49% in last trading session and ended the day at $16.30. POT Gross Margin is 38.50% and its has a return on assets of 8.30%. Potash Corporation of Saskatchewan Inc. (NYSE:POT) quarterly performance is -24.38%.

Potash Corporation of Saskatchewan Inc. (NYSE:POT) announced that its Board of Directors has declared a quarterly dividend of US $0.38 per share payable February 4, 2016 to shareholders of record January 14, 2016.

Amber Road, Inc. (NYSE:AMBR) ended the last trading day at $4.14. Company weekly volatility is calculated as 6.41% and price to cash ratio as 5.03. Amber Road, Inc. (NYSE:AMBR) showed a weekly performance of -4.39%.

Amber Road, Inc. (NYSE:AMBR) announced that it will report its fourth quarter and full year 2015 financial results after the U.S. financial markets close on Thursday, February 11, 2016.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) caters to the Healthcare space. Its weekly performance is -60.26%. On the last day of trading company shares ended up at $14.28. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) distance from 50-day simple moving average (SMA50) is -9.68%.

On 15 January, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) said that, FDA Briefing Information, the FDA also posted the Company’s Briefing Information, which includes an addendum submitted by the Company with a comparison of 4 year ambulation data between study 202 subjects and an external control (collectively, the “Sarepta Briefing Information”), for the Advisory Committee Meeting on its web site. The Company is not responsible for the content of, nor the statements made in, the FDA Briefing Information.

Titan Pharmaceuticals Inc. (NASDAQ:TTNP) shares moved up 3.33% in last trading session and ended the day at $3.10. TTNP has a return on assets of -53.10%.

Titan Pharmaceuticals Inc. (NASDAQ:TTNP) and partner Braeburn Pharmaceuticals announced that the Psychopharmacologic Drugs Advisory Committee (PDAC) of the U.S. Food and Drug Administration (FDA) voted 12 to 5 in favor of approving Probuphine, the first long-acting, subdermal buprenorphine implant for the maintenance treatment of opioid addiction, in stable patients receiving 8mg or less per day of buprenorphine. The Committee’s vote followed presentation and discussion of data regarding Probuphine’s efficacy, safety, and risk-benefit profile. The New Drug Application (NDA) for Probuphine was resubmitted to the FDA in August 2015, and accepted by the FDA in September 2015. A target agency action date has been set for February 27, 2016.

ECA Marcellus Trust I (NYSE:ECT) shares moved up 10.38% in last trading session and ended the day at $1.17. ECT has a return on assets of 10.60%. ECA Marcellus Trust I (NYSE:ECT) quarterly performance is -37.57%.

Zacks Investment Research cut shares of ECA Marcellus Trust I (NYSE:ECT) from a hold rating to a sell rating in a research report published on Monday, ARN reports.